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Abstract 
Background: Inflammatory Bowell Disease is a chronic idiopathic disease and 
immunological disorder of the gastrointestinal tract that includes Crohn Disease (CD) 
and Ulcerative Colitis (UC). However those diseases affect people in different ways, 
CD can affects any part of the gastrointestinal tract, but most commonly, the terminal 
ileum, cecum, peri-anal area and colon. UC most commonly affects the rectum and 
extends proximally in a continuum. Immune response is altered in an IBD situation 
because mucosa’s disruption and consequent pathogen infiltration. Ncf1* mutated mice 
present a NADPH complex incapable of producing ROS. This alteration compromises 
immune system in order to react to pathogens and solve inflammation. 
 
Methods: Two experiments were made. In first colitis was induced in Ncf1* and Wild-
Type (WT) mice by a 1st 7-days cycle of dextran sulfate sodium (DSS), with 21 days 
resting. In the second experiment colitis was induced in Ncf1* and WT by a 1st 7-days 
cycle of DSS followed by 14 days of resting and then a 2nd 7-days cycle of DSS. 
Physical scores were evaluated during all experiment. Immune lymph node populations 
were analyzed by flow citometry and morphological alterations of the colon mucosa 
were assessed by histology. 
 
Results: Colitis showed more severe in Ncf1* mice comparing to WT mice which is 
confirmed by clinical scores. Ncf1* presented a more accentuated inflammation with 
more tendency to chronicity and dysplasia, with a more aberrant immunological 
response in Ncf1*. Ncf1* mice presented more difficulties in solving inflammation 
process. 
 
Conclusion: The absence of ROS leads to an increase severity in colitis with more 
tendency to chronicity and dysplasia. Ncf1* mice response to DSS induced colitis, 
showed ROS importance in solving inflammation process.  
 
 
Key-words: reactive-oxygen species; NADPH-oxidase complex; colitis; immune 
response; dysplasia.  
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Resumo 
Introdução: Doença inflamatória intestinal (DII) é uma doença crónica, idiopática e 
imunológica do trato gastrointestinal inclui a doença de Crohn e a Colite Ulcerosa. 
Todavia estas doenças afectam a população de formas distintas, a doença de Crohn pode 
afectar qualquer parte do trato gastrointestinal, mas mais frequentemente o ileum 
terminal, o cécum, área peri-anal e o colon. A colite Ulcerosa afecta mais 
frequentemente o recto estende-se proximalmente em continuum. A resposta 
imunológica está alterada numa situação de DII devido à destruição da mucosa 
intestinal e consequente infiltração de patogéneos. Os murganhos com a mutação Ncf1* 
apresentam um complexo NADPH incapaz de produzir ROS. Esta alteração 
compromete o Sistema imunológico e a sua capacidade de resolução da inflamação.  
 
Métodos: Realizaram-se duas experiências. Na primeira foi induzida colite nos 
murganhos mutados Ncf1* e nos WT com um 1º ciclo de 7 dias de DSS, seguido de 21 
dias de descanso. Na segunda experiência foi administrado 1º ciclo de 7 dias de DSS, 
seguido de 14 dias de descanso e de um novo ciclo de 7 dias de DSS. Foram avaliados 
parâmetros físicos. Analisaram-se as populações imunológicas através de cirtometria de 
fluxo e as alterações morfológicas foram analisadas por histologia. 
 
Resultados: A colite mostrou-se mais severa nos murganhos Ncf1* comparativamente 
aos WT conforme indicam os parâmetros clínicos. Os murganhos Ncf1* apresentaram 
uma inflamação mais acentuada com maior tendência à cronicidade e displasia. A 
resposta imunológica mostrou-se mais aberrante nos murganhos Ncf1* com maior 
dificuldade em resolver o processo inflamatório.  
 
Conclusão: A ausência de ROS leva a um aumento na severidade da colite e a uma 
maior tendência à cronicidade e displasia. Os murganhos Ncf1* mostraram a 
importância dos ROS na resolução do processo inflamatório. 
 
 
Palavras-chave: espécies reactivas de oxigénio; complexo NADPH-oxidase; colite; 
resposta imune; displasia.
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1. Introduction 
 Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) is a chronic relapsing idiopathic, 
immunological disorder of gastrointestinal tract, leading to long-term and sometimes 
irreversible impairment of gastro-intestinal structure and function. IBD presents two 
major forms of the pathogenesis, Crohn's disease (CD) and Ulcerative Colitis (UC). 
Accumulating evidence suggests that IBD arises from an inappropriate inflammatory 
immune response to intestinal microbes in a genetically susceptible host.  Although UC 
and CD share many clinical and pathological features they have some different key 
characteristics that suggest that the main pathological processes in the two forms of the 
disease are distinct (Blumberg et al, 2001) (Bouma Strober, 2003) (Martins and 
Peppercorn et al, 2004) (Sartor, 2006)  (Hanauer, 2006) (Abraham et al, 2009) (Xavier 
and Podolsky, 2007) (Lai S. et al. 2011). 
 In Crohn's disease any part of gastrointestinal tract can be affected, but most 
commonly, the terminal ileum, cecum, peri-anal area and colon. It is characterized by 
the presence of normal segments of the bowel between affected regions. Histologically 
CD is characterized by transmural inflammation involving any part of the 
gastrointestinal tract, dense infiltration of lymphocytes and macrophages, presence of 
granulomas in up to 60% of the patients and fissuring ulceration (Blumberg, 2001) 
(Bouma and Strober, 2003) (Martins and Peppercorn, 2004)  (Baumgart and Sandborn, 
2007) (Xavier and Podolsky, 2007) (Strober, F. et al, 2007) (Strober, Fuss et al. 2007) 
(Abraham and Cho, 2009). 
 In Ulcerative Colitis, the inflammatory process involves rectum and extends 
proximally in a continuum. Histologically,  inflammation involves superficial mucosal 
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layers with infiltration of lymphocytes, granulocytes and loss of goblet cells, presence 
of ulcerations and crypt abscesses can also occur (Bouma and Strober 2003) (Martins 
and Peppercorn 2004) (Strober, F. et al, 2007) (Abraham and Cho 2009). 
1.1.1 Epidemiology 
 There is a bimodal distribution of the disease in population. Most individuals (up 
to 25% of the patients) (Benchimol, F. et al, 2010) are diagnosed during a first peak 
between ages 15 and 40 years, with a second peak occurring in individuals older than 60 
years, demonstrating that CD and UC can affect people of all ages (Bonen and Cho, 
2003)  (Martins and Peppercorn, 2004) (Hanauer, 2006) (Yan Z. et al, 2011). 
 The colon is the most common macroscopic site of disease in very young 
children and differentiation of UC from colonic CD may be difficult. Childhood-onset 
of UC is typically extensive, whereas adults are equally likely to develop UC confined 
to the distal colon. CD affects mostly males after puberty and females in adult age 
(Benchimol F. et al, 2010). 
 As recently reviewed, the incidence and prevalence of CD and UC varies greatly 
around the globe, all races and ethnic groups are affected and the disease incidence is 
rising internationally (Martins and Peppercorn, 2004). IBD shows no large genetic 
background shifts and as it was seen in twins studies, genetic has a small role on it, so 
environmental factors importance in the disease growths. 
 It is postulated that ‘‘Westernization’’ of society accounts for recent increases in 
the incidence of IBD. Areas with the highest incidence and prevalence of IBD are in 
Northern Europe and North America. Although during the past few decades the racial 
gap has been closing, as there has been an increasing incidence of IBD (Bonen and Cho, 
2003) (Martins and Peppercorn, 2004) (Hanauer, 2006) (Baumgart and Carding, 2007) 
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(Benchimol, F. et al, 2010), (Hansen, T. et al, 2010). Besides westernization, there are 
some other theories/hypothesis trying to explain the increase and the onset of the 
disease.  The ‘‘cold chain hypothesis’’ suggests that refrigeration has altered the 
bacterial content of our diet, resulting in the increased growth of disease triggering 
organisms. As with atopic diseases, the ‘‘hygiene hypothesis’’ offers an alternative for 
the increase of IBD, asthma, rheumatoid arthritis, and type I diabetes in our society. The 
theory suggests that exposure to pathogens and parasites early in life, stimulates 
protective immunity that will prevent later an aggressive immunologic processes. So a 
cleaner environment, smaller families, and lower exposure to farm animals, in other 
words, excessive sanitation might limit the exposure to environmental antigens and 
impair the functional maturation of mucosal immune system and induction of immune 
tolerance, leading to the increase risk for IBD (Sartor, 2006) (Hanauer, 2006) 
(Baumgart and Carding, 2007) (Benchimol, F. et al, 2010).  The most widely held 
hypothesis on the pathogenesis of IBD is that overly aggressive acquired (T cell) 
immune responses to a subset, of imbalance in the proportions of "protective" and 
"harmful" commensal enteric bacteria (dysbiosis) develop in genetically susceptible 
hosts, and environmental factors precipitate the onset or reactivation of disease. (Sartor, 
2006)  (Hansen T. et al, 2010). 
1.1.1.1 Environmental triggers 
 Several previous studies have implicated environmental factors as triggers in 
genetically predisposed hosts to IBD. The environmental triggers act in IBD by 
altering/disrupting the mucosal barrier integrity, altering immune response, or the 
luminal microenvironment, each of which have an impact on susceptibility to 
inflammation (Martins and Peppercorn, 2004) (Sartor, 2006). 
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Antibiotics and diet can alter the luminal flora, dietary additives such as 
aluminum and iron have a well-described adjuvant activity and stimulate bacterial 
virulence (Sartor, 2006). The pre-morbid state in Crohn’s disease includes a diet which 
is more likely to contain more refined sugar, less fiber, and less raw fruit and 
vegetables. The refined sugar finding has been supported by a case–control study from 
Sweden demonstrating a positive link between sucrose intake and Crohn’s as well as 
protective effects of wholegrain bread, muesli and coffee and a  high risk associated 
with fast foods (Baumgart and Carding, 2007) (Hansen T. et al, 2010). Vegetable intake 
and coffee were protective for UC, and fast foods conferred a major risk, a previous 
study suggested that ‘‘dietary influences may alter the milieu of the intestinal lumen or 
modify the intestinal flora and promote the growth of an infective agent or its invasion 
of the gut wall’’. It may well be that pre-morbid diet provides either specific or 
sufficient distal intestinal substrates which allow the invasion of a pathological microbe 
or the establishment of dysbiosis (Hansen T. et al, 2010). 
 Nonsteroidal anti-inflammatory drugs and acute infections can cause 
inflammation, which results in increased mucosal permeability, leading to increase 
uptake of commensal bacterial antigens, that stimulate the T-cell-mediated intestinal 
inflammation (Martins and Peppercorn, 2004) (Sartor, 2006).   
 Stress can alter mucosal permeability, mucosal blood flow, epithelial electrolyte, 
water secretion and expression of cytokines and neuropeptides. All referred factors 
seem to increase the likelihood of relapse in patients with quiescent disease (Sartor, 
2006) (Baumgart and Carding, 2007).  
1.1.1.2 Luminal antigens and gut flora 
 Studies in several different animal models have demonstrated that luminal flora 
is required for IBD to develop in a susceptible host. Genetically susceptible animals that 
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are maintained in a germ-free environment from birth don't develop immune system 
activation and colitis. When these same animals acquire luminal flora, they develop 
activation of their immune systems and colitis (Blumberg, 2001) (Hanauer, 2006). The 
normal mucosal microflora is required to initiate or maintain the inflammatory process, 
presumably by providing one or more antigens or co-stimulatory factors that drive the 
immune response (Martins and Peppercorn, 2004). When genetically susceptible, hosts 
develop an aggressive T-cell response towards luminal commensal bacteria. 
 Antigens from microflora, are present in the body since the birth, so they might 
be subjected to an intra-thymic processing that allows immune system to distinguish 
self-antigens from non-self-antigens, so the hypothesis that organism could be reacting 
to this antigens and developing an autoimmune response, makes chronic mucosal 
inflammation of IBD to be though as an autoimmune disease  (Sartor, 2006) (Bouma 
and Strober, 2003). 
1.1.1.3 The presence of abnormal microflora 
 One major hypothesis regarding IBD pathogenesis, views the disease as a result 
from a problem with the microflora, which induces a pathologic response from a normal 
mucosal immune system. Two types of evidence support this hypothesis. Some data 
suggest that IBD is associated with pathologic organisms that establish a type of low-
grade infection of the mucosa leading to the inflammatory response that characterizes 
the disease. Other data suggest that IBD patients have a defective epithelial barrier that 
enables nonpathologic organism’s proliferation in close juxtaposition to elements of the 
mucosal immune system, again leading to the inflammatory response that characterizes 
the disease. 
 A previous study by Swidsinski et al. demonstrated higher amounts of mucosa-
associated bacteria in biopsy tissue obtained from patients with IBD compared with 
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tissue obtained from control subjects. Darfeuille-Michaud et al also reported increased 
numbers of mucosa-associated bacteria in IBD. In this case, a pathogen-like invasive E. 
coli was associated with the mucosa of 20%–40% of illeal biopsy specimens from CD 
patients as compared with the mucosa of 6% of specimens from controls. In contrast, 
about 4% of colonic specimens from both CD patients and from control subjects 
harbored invasive bacteria, compared with 12% of specimens from UC patients (Strober 
F. et al, 2007). Studies shown that CD fecal samples have a marked reduction in 
diversity. In healthy individuals, 95% of the bacteria in stool samples belong to 
bacteroides however, IBD patients showed a marked reduction of these organisms. A 
very strong association has been shown between illeal CD and the lack of F. prausnitzii 
showing dysbiosis in infectious colitis. Studies that have cultured the colonic mucosa 
after removal of overlying mucus have shown that mucosa in healthy individuals is 
relatively sterile but that there is a marked increase in bacteria populations in CD and to 
a lesser extent in UC (Bai and Ouyang, 2006) (Friswell C. et al, 2010) . Bacterial 
enzyme activities, especially b-D-galactosidase, were also decreased in fecal extracts 
from CD patients, correlated with the decrease of bifidobacteria counts. Significant 
decrease in the number of anaerobic bacteria, anaerobic gram negatives and 
lactobacillus was shown in patients with active UC. Luminal microflora in IBD patients 
lost the anti-inflammatory function that exists in normal condition, with a reduction in 
the number of anaerobic bacteria and lactobacillus (Bai and Ouyang, 2006). 
  Complementary studies using molecular techniques to identify specific bacterial 
groups have also been applied to the study of the bacterial microflora in IBD, however 
these studies do not support the presence of a specific, pathogenic organism in IBD 
(Strober F. et al, 2007). 
Chapter 1 – Introduction 
 
7 
 
 Genetic 
1.2.1 Familial aggregation in IBD 
 Epidemiological and family studies have provided great evidence that genetic 
factors have a role in determining susceptibility to IBD. First-degree patients’ relatives 
with IBD have a 4-to-20-fold increased risk. People with CD have a first-degree relative 
with the disease in 2% of the cases and with IBD in 5% of the cases. Regarding people 
with UC, they usually have a first-degree relative with the disease in 5% of the cases, 
and with inflammatory bowel disease in 8% of the cases (Baumgart and Carding, 2007) 
(Bonen and Cho, 2003). However, despite the evidence supporting a genetic 
predisposition, most patients with IBD have no close relatives with IBD  (Martins and 
Peppercorn, 2004) (Bouma and Strober, 2003). 
1.2.2 Susceptibility genes involved in IBD 
 There have been two general approaches for gene identification in complex 
genetic disorders, like IBD, the use of genome-wide linkage studies and the testing of 
candidate genes. The tendency appears to be that the implicated genes in IBD regulate 
several biologic functions, including immunoregulation, mucosal barrier integrity and 
microbial clearance and/or homeostasis (Sartor, 2006). Nowadays several regions on 
chromosomes, 16, 12, 6, 14, 5, 19, 1, 16, and 3 have been renamed as IBD1–9, 
respectively, and in a few cases the gene or genes underlying the different chromosome 
loci that are linked to IBD have been identified. 
IBD-1: CARD15, also known as NOD2, (caspase recruitment domain family member 
15), which is expressed in macrophages, dendritic cells, epithelial cells and paneth cells 
(Martins and Peppercorn, 2004) (Bouma and Strober, 2003) (Sartor, 2006) (Cho and 
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Weaver, 2007) (Van Limbergen R. et al, 2007) (Marks and Segal, 2008) (Abraham and 
Cho, 2009). 
 There are three mutations/polymorphisms associated with NOD2/CARD15, 
causing amino-acid substitutions, Arg702Trp and Gly908Arg and the frameshift 
1007fs—found within the region of CARD15 that encodes a leucine-rich repeat, which 
is responsible for bacterial recognition. At least one of these mutations is present in 25–
35% of CD patients of European ancestry. The leucine-rich repeat region of CARD15 
binds muramyl dipeptide (MDP), which is the biologically active moiety of 
peptidoglycan, a ubiquitous cell-wall polymer found in almost all bacteria. The binding 
of MDP to CARD15 activates nuclear factor NF-κB through a receptor-interacting 
serine-theronine kinase-2 (RIPK2) - dependent signaling pathway, which forms part of 
a central signaling pathway that stimulates the transcription of multiple genes that 
encode both pro-inflammatory and protective molecules. The mutations causing 
Arg702Trp, Gly908Arg and 1007fs cause defective MDP binding (Mathew and Lewis, 
2004) (Sartor, 2006) (Xavier and Podolsky, 2007) (Strober F. et al, 2007) (Cho and 
Weaver, 2007) (Van Limbergen R. et al, 2007) (Marks and Segal, 2008) (Chen, L. et al, 
2011). The variant forms of CARD15 result in reduced macrophage activation of NF-κB 
pathway and increased luminal bacterial populations. It would be expected this to result 
in a lower inflammatory response however there is the occurrence of increased 
inflammation dependent on NF-kB in individuals bearing a mutation impairing NF-kB 
activation. One theory postulate was that impaired NOD2 function led to a host defense 
defect that allowed increased bacterial colonization of the gut wall and then later to 
stimulation of NF-κB via NOD2-independent mechanisms (Strober F. et al, 2007) (Van 
Limbergen R. et al, 2007). Another hypothesis was prompted by the observation that 
the ligand for TLR2, peptidoglycan, can activate NF-κB independently of NOD2 
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(Strober, Fuss et al. 2007). NOD2 polymorphisms, when expressed within enterocytes 
and Paneth cells are associated with diminished production of anti-bacterial α-defensins 
(Xavier and Podolsky, 2007). This might lead to bacterial overgrowth and subsequent 
infection and chronic inflammation. Despite the presented facts, some studies suggest 
that NOD2 only plays a small role in the pathogenesis of the disease, because of its 
strongest association only with CD and the polymorphisms occur predominantly in 
patients with small bowel disease and are restricted to certain racial groups, which is 
indicative of the complexities of a multifactorial disorder  (Marks and Segal, 2008) 
(Abraham and Cho, 2009). In patients with variant CARD15, homozygotes for this 
variant gene have a 20- to 40-fold increased risk of developing CD, whereas the 
heterozygotes have only 2- to 4-fold increased risk (Martins and Peppercorn, 
2004)(Bouma and Strober, 2003) (Abraham and Cho, 2009) (Bonen and Cho, 
2003).Primary-monocyte-derived macrophages from patients with CD  who are  
homozygous for the truncating mutation in the LRR sensor domain (Leu1007fsinsC) 
have a globally blunted transcriptional response to MDP. In contrast, NOD2 frameshift-
mutation knock-in mice have an enhanced response to MDP and are susceptible to 
dextran sodium sulphate colitis (Xavier and Podolsky, 2007) (Cho and Abraham, 2007). 
 Regarding the linkage studies, no evidence was observed in CD-UC or UC- UC 
affected relative pairs, indicating that the susceptibility gene at IBD1 likely conferred 
susceptibility only for CD (Cho and Abraham, 2007). 
IBD-3, on chromosome 6p encompassing the major histocompatibility complex 
(HLA) has been implicated consistently for both CD and UC in various linkage studies. 
One study showed that the linkage at IBD3 locus was sex-specific, being more observed 
among either CD- or UC-affected males, further showing the likely complexity of 
disease pathogenesis. Both data from linkage and epidemiologic studies estimate the 
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relative contribution of HLA region to overall genetic risk as 64% to 100% for UC and 
10% to 33% for CD. HLA class II associations contribute to overall disease 
pathogenesis, especially for UC. Previous studies between 1966 and 1998 showed 
significant positive associations in UC to DR2, DR9, and DRB1*0103, whereas a 
negative association was found for DR4. For CD, a positive association was found with 
DR7, DRB3*0301, and DQ4, and a negative association with DR2 and DR3. 
Furthermore, this region contains the TNF gene, for which functional promoter 
polymorphisms affecting TNF expression have been reported. TNF expression involves 
a variety of regulatory elements located in the gene’s promoter region. Three promoter 
polymorphisms (in the -1031C, -863A, and -857T regions) have been found to be 
associated with susceptibility and progression of CD in a Japanese population and 
between CD and the -1031C allele in a European population  (Bonen and Cho, 2003, 
Cho and Weaver, 2007)  (Van Limbergen, R. et al, 2007) (Mathew and Lewis, 2004). 
NADPH oxidase, is a complex formed by several accessory proteins that 
produces ROS and plays an essential role in cellular response in microbial invasion. 
Genetic mutations in genes encoding components of the complex, results in both X-
linked and autosomal recessive forms of Chronic Granulomatous Disease (CGD), which 
often develops in intestinal inflammation that is histologically similar to Crohn's colitis. 
An SNP within the first intron of NCF4 (encoding p40Pphox subunit of the complex) was 
identified as a CD-specific susceptibility gene. In a recent study Muise et al. reported a 
novel missense variant in NCF2 (encoding p67phox subunit) in patients with very early 
onset IBD (VEO-IBD) that resulted in neutrophil dysfunction and susceptibility to CD. 
Patients with the heterozygote variant c.113 G→A (p67phox R38Q), had extensive 
colonic disease, some had perianal disease and had significant arthritis. In their study 
Muise et al also described novel associations between NADPH oxidase complex gene 
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RAC2 and CD, associated with enhanced susceptibility to IBD (Xavier and Podolsky 
,2007) (Wirtz and Neurath, 2007)  (Cho and Weaver, 2007)  (Van Limbergen R. et al, 
2007) (Rioux, X. et al, 2007) (Muise X. et al, 2012). 
 Immune Response 
 Both CD and UC patients have activated innate (macrophage and neutrophil), 
acquired (B and T cell) immune responses and loss of tolerance to enteric commensal 
bacteria, either because of dysfunction in the primary or secondary mechanisms that 
normally drive and regulate such responses, or because of some dysfunction in the 
intestinal epithelial barrier that leads to inappropriate penetration of microbial antigens 
(Blumberg, 2001) (Sartor, 2006).  CD and UC are both characterized by enhanced 
recruitment and retention of effector macrophages, neutrophils and T cells into the 
inflamed intestine, where they are activated and release pro-inflammatory cytokines. 
Accumulation of effector cells in the inflamed intestine is a result of enhanced 
recruitment as well as prolonged survival caused by decreased cellular apoptosis (Sartor 
2006).  
1.3.1 Innate immune responses 
 Macrophages and dendritic cells in lamina propria are increased in absolute 
number and have an activated phenotype in both forms of IBD.. Production of pro-
inflammatory cytokines and chemokines is enhanced in IBD and expression of adhesion 
molecules and co-stimulatory molecules is also increased. Cells involved in innate 
immune response are activated and the expression of most pro-inflammatory cytokines 
and chemokines is upregulated in both CD and UC. Th1 and Th17-related cytokines 
involved in innate immunity, like IL-12, IL-23 and IL-27 are, however, selectively 
activated in CD (Sartor, 2006), (Martins and Peppercorn, 2004) (Abraham and Cho, 
2009) Activation of NF-κB stimulates expression of numerous molecules relevant to  
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IBD pathogenesis. These include molecules involved in the inflammatory response, 
such as IL-1β, TNF, IL-6, IL-8 and other chemokines, ICAM1 and other adhesion 
molecules and co-stimulatory molecules including CD40, CD80, CD86 and the 
inducible T-cell co-stimulator ICOS. Expression of each of these pro-inflammatory 
molecules is increased in active IBD. In contrast, cytokines that induce Th1 and Th17 
responses are selectively up regulated in active CD but not in UC. Selective inhibition 
of most of this cytokines attenuates the onset of experimental colitis (Sartor, 2006). 
Neutrophils cause tissue damage, which seems to be exacerbated in IBD patients due to 
an extended lifespan of impaired apoptosis,  through the release of nonspecific 
inflammatory mediators, such as Reactive Oxygen Intermediates, lipid mediators, 
proteases and secrete cytokines like IL-1β and TNF-α (Brown and Mayer, 2007). 
1.3.2 Adaptive immune responses by T cells 
There is a difference between T-cell response between CD and UC, so they should be 
considered separately (Bouma and Strober, 2003). 
1.3.2.1 Crohn’s disease  
 A variety of T-cell defects have been observed in IBD patients this include 
defective T-cell apoptosis, which has been associated with a rapid cell cycle in CD, 
defects in regulatory T-cell activation and function and mouse models have 
demonstrated that both excessive pro-inflammatory and deficient anti-inflammatory 
responses may manifest in IBD (Brown and Mayer, 2007). Most mouse models present 
a similar cytokine profile to the one seen in human CD. The Th1 traditional cytokine 
profile is dominant in patients with CD, and is mediated by IFN-γ, the production of 
which is stimulated by IL-12, produced by antigen-presenting cells (APCs). CD can 
also present a Th17 cytokine profile, where IL-17 mediates Th17 responses. This 
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cytokine profile is stimulated by  IL-6, TGF-β and IL-23 production by innate immune 
cells and APCs, especially dendritic cells (Brown and Mayer, 2007). 
1.3.2.2 Ulcerative Colitis 
 In UC there's also a range of T-cell defects that can be observed, defective T-cell 
apoptosis in UC has been associated with a slower than normal cell cycle and defects in 
regulatory cytokines, TGF-β or IL-10 are associated with the development of UC 
(Brown and Mayer, 2007).This disease is considered to have a Th2 cytokine profile, but 
the concentrations of IL-4 and IL-5 which are characteristically elevated in this type of 
response, have been variable in UC tissues. UC has been associated with the production 
of various autoantibodies, such as neutrophil cytoplasmatic antibody (pANCA) and 
anti-tropomyosin, which might be indicative of a Th2-mediated immune response, with 
IgG1 and IgG4 overproduction predominating in UC.  So, this way UC is considered to 
have an atypical Th2-type response, mediated by NK T cells that secrete IL-13 (Bouma 
and Strober, 2003) (Martins and Peppercorn, 2004) (Sartor, 2006). 
1.3.3 Adaptive immune response by B cells  
 B cells produce antibodies to both bacterial and nonbacterial antigens in mouse 
and human IBD. This supports the hypothesis that there is a break down in mucosal 
tolerance. Several antibodies against microbial products are increasingly recognized in 
IBD, this include anti-Saccharomyces cerevisae (ASCA), anti-12, anti-Ompc and anti-
flagellin antibody CBir1, being that78% of patients react at least to one of these 
antibodies (Abraham and Cho, 2009). This implies that rather than a global loss of 
tolerance, different patients may form one or more specific antibodies and the 
combinations present may help stratify disease subtypes (Brown and Mayer, 2007). 
Chapter 1 – Introduction 
 
14 
 
1.3.4 Malfunction of the immune system 
 It is accepted that IBD results from an inappropriate response of a defective 
mucosal immune system. But how and why microbial antigens induce an inappropriate 
inflammatory response? Experimental evidence from studies in vitro, in animals, and in 
human beings suggest that several, not mutually exclusive, pathways might result in 
inflammatory cascades (Baumgart and Carding, 2007). 
 First, the epithelial barrier is leaky in people with IBD, s-studies have shown 
lower epithelial resistance and increased permeability of the inflamed and non-inflamed 
mucosa in CD and UC (Baumgart and Carding, 2007). The paracellular space has 
increased permeability and the regulation of tight junctions is defective (Abraham and 
Cho, 2009) (Strober, F. et al, 2007). This barrier defect might be inherent or induced by 
infection or nonsteroidal anti-inflammatory drugs (Brown and Mayer 2007). The 
inflammatory response often results in continued epithelial injury, which causes 
erosions, ulcerations and a decrease in defensins’ production (Strober, F. et al, 2007). 
The result is increased exposure to intestinal microbiota and amplification of the 
inflammatory response (Abraham and Cho 2009). The importance of the epithelial 
barrier in disease predisposition is supported by the finding of abnormal intestinal 
permeability in some first-degree relatives with CD (Xavier and Podolsky, 2007). 
 Innate immune mechanisms of the epithelial layer present altered too  An 
upregulation of NOD2 in epithelial cells, which can augment itself further in a feedback 
loop, when the NFκB cascade is activated has also been reported, which might 
compromise the ability of the host to eliminate invasive and pathogenic microbes 
resulting in chronic inflammation (Baumgart and Carding, 2007). 
 Animal and in-vitro studies suggested that dendritic cells incorrectly recognize 
commensal bacteria and induce a Th1 and possibly Th17, pro-inflammatory immune 
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responses normally directed to pathogens, (Baumgart and Carding, 2007) in other 
words, loss of tolerance to resident microbial flora, proposes that the disease could be 
caused by an abnormal immune response to one enteric pathogen (Brown and Mayer, 
2007) (Strober, W. et al, 2007). No specific dietary component has been identified, 
although several infectious agents have been proposed, including species of 
Myobacterium, Listeria, Yersinia, and Escherichia coli. Immune responses are initiated 
when either cytotoxic T lymphocyte CD8cells or CD4Th cells in the intestinal lumen 
recognize a bacterial antigen (Cho and Abraham, 2007). 
 IBD presents disturbed clearance of over-reactive or auto-reactive T-cell 
populations. Due to a failure of central (thymic) and peripheral tolerance, activated T 
cells persist and do not undergo apoptosis (Baumgart and Carding, 2007). Defective 
mucosal T-cell apoptosis is likely to play a pivotal play role in IBD, support for this 
hypothesis comes from studies that investigated the Bcl-2/Bax protein family, where 
Bcl-2 protein protects from apoptosis and Bax promotes apoptosis. Levels of expression 
of Bax protein are markedly reduced in inflamed UC colonic epithelium. The alteration 
in the ration of Bac/Bcl-2 in CD suggests an imbalance in these proteins that may favor 
resistance of mucosal T cells to apoptotic signals (Cho and Abraham, 2007). The 
autophagy pathway contributes to T-cell tolerance at multiple levels, which suggests 
that polymorphisms of autophagy genes associated with CD could increase a patient’s 
susceptibility to intestinal inflammation through defects in T-cell tolerance (Abraham 
and Cho, 2009).  
1.3.5 Human studies/Animal studies 
 An important advance in the study of IBD has been the discovery and analysis of 
a variety of mouse models of intestinal inflammation that resemble the human IBD. The 
mouse models fit broadly in four groups: a) spontaneous colitis, as a result of naturally 
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occurring genetic abnormality; b) spontaneous colitis that occurs in mice with particular 
genetic defects produced either by gene targeting or introduction of a transgene; c) 
colitis induced by exposure to a haptenating agent or another type of causative agent; d) 
colitis induced by transferring T-cell populations lacking regulatory cells into a severely 
lymphopenic host that lacks endogenous regulatory cells (Bouma and Strober, 2003)  
 Intestinal inflammation occurs in models in which there is a clear deficiency in 
the production or function of a known regulatory cytokine, such as IL-10 knockout 
mice, or mice with defective TGF-β signaling and colitis occurs in mice in which 
regulatory T cells fail to develop properly (Bouma and Strober, 2003). These studies 
provide compelling evidence that the nature of the host defenses, rather than the 
biological properties of a luminal bacterial species per se, may determine the functional 
outcome of that interaction (Xavier and Podolsky, 2007).   
  DSS colitis model, which consists in feeding mice for several days with DSS 
polymers in the drinking water, induces a very reproducible acute colitis characterized 
by bloody diarrhea, ulcerations and infiltrations with granulocytes. It is believed that 
DSS is directly toxic to gut epithelial cells of the basal crypts and therefore affects the 
integrity of the mucosal barrier. As T- and B-cell deficient C.B-17scid or Rag1−/− mice 
also develop severe colitis. The adaptive immune system obviously does not play a 
major part (at least in the acute phase) in this model. Hence, the acute DSS colitis model 
is particularly useful to study the contribution of innate immune mechanisms of colitis. 
In addition, the DSS model has been shown to be suitable to study epithelial repair 
mechanisms. Studies with TLR4−/− and MyD88−/− mice suggest that TLR signaling is 
required to limit bacterial translocation after DSS induced intestinal epithelial injury 
suggesting that TLR signaling is important for the maintenance of the epithelial barrier. 
In susceptible strains, the administration of DSS for several cycles (e.g., 7 days DSS, 14 
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days water) results in chronic colitis and if combined with a single initial dose of the 
genotoxic colon carcinogen azoxymethane (AOM), in inflammation-associated 
colorectal cancer. Patients with UC have an increased risk for the development of colon 
cancer. As colonic inflammation is suggested to play a key role in IBD-related 
colorectal cancer, the AOM/DSS model is a very useful tool to study mechanisms 
linking inflammation to colon carcinogenesis (Wirtz and Neurath, 2007). 
 TNBS/Oxazolone colitis model, where colitis can be induced in susceptible 
mouse strains by intrarectal instillation of TNBS/ DNBS or Oxazolone dissolved in 
ethanol. Ethanol is required to break the mucosal barrier, whereas TNBS/Oxazolone is 
believed to haptenize colonic autologous or microbiota proteins rendering them 
immunogenic to the host immune system. As CD4+ T cells have been shown to play a 
central role in chronic TNBS colitis, this model is useful to study T helper cell-
dependent mucosal immune responses. The TNBS colitis model has been very useful in 
studying many important aspects of gut inflammation, including cytokine secretion 
patterns, mechanisms of oral tolerance, cell adhesion and immunotherapy. Murine 
TNBS colitis has been initially described in SJL/J mice, a mouse strain with high 
susceptibility that develops chronic TNBS colitis characterized by a predominant Th1-
mediated immune response with dense infiltrations of lymphocytes/macrophages and 
thickening of the colon wall. However, studies with IFN-γ−/− mice on a Balb/c 
background showed that in these mice TNBS colitis may be associated with a Th2-
mediated colonic patch hypertrophy. In SJL/J mice, oxazolone colitis has been shown to 
affect only the distal colon and particularly mucosal layers. Histological features and an 
elevated production of Th2 cytokines (IL-4, IL-5 and IL-13) of unstimulated and αCD3/ 
αCD28-stimulated lamina propria T cells are in these mice, in some aspects, similar to 
characteristics that have been observed in human UC. Oxazolone colitis is one of the 
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few models suitable to study the contribution of the Th2-dependent immune response to 
intestinal inflammation (Wirtz and Neurath, 2007). 
 In NOD 2 model three different mouse models harboring nonfunctional NOD2 
have been developed. The first mouse model, which carries a NOD22939insC mutation 
similar to the human CD-associated NOD23020insC frameshift mutation, is susceptible to 
DSS induced intestinal injury. Unlike chronic IBD models that do not develop disease 
under germ-free conditions, DSS-induced acute intestinal injury is exacerbated in the 
absence of commensal flora. Therefore, the increased susceptibility of NOD2 mutant 
mice to DSS-induced intestinal injury suggests the involvement of NOD2 in commensal 
flora-mediated protective immunity, particularly during the acute inflammatory phase. 
The second model is a NOD2 KO mouse strain that was generated by a deletion of exon 
1. This characterized by altered TLR-2 signaling. The production of IL-12p70 by APCs 
in this model is increased in response to TLR2 stimulation, suggesting an inhibitory role 
of NOD2 in TLR2-mediated Th1 responses. The third model is another NOD2 KO 
mouse strain that was generated by deletion of exon 3. This mouse strain is more 
susceptible to a Listeria monocytogene infection because of impaired Paneth cell 
function and a reduced production of antibacterial peptides such as cryptidin and 
defensins. The importance of Paneth cell function in the suppression of IBD is further 
supported by recent data from a conditional KO mouse strain deficient of another CD 
susceptibility gene, XBP1, in epithelial cells. This epithelial cell-specific XBP1 deletion 
results in an impaired Paneth cell development and consequent development of ileitis. 
Indeed, abnormally low production of antibacterial peptides such as α-defensins by 
Paneth cells is proposed to be a primary defect in CD particularly illeal CD (Liu Y. et 
al, 2011)(Liu, Yang et al. 2011) (Mizoguchi and Mizoguchi 2010). 
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Besides all IBD models it is noteworthy that none of the current animal models 
of IBD is ideal, and efforts to create an experimental model of human IBD using toxic 
chemicals fail to modulate the complex interaction of multiple factors such as genetic, 
immunologic, environmental, and psychologic components in the pathophysiology of 
IBD. 
1.3.6 Treatments  
 The mainstays of CD and UC treatment are to achieve and maintain disease 
remission with improved health-related quality of life, fewer hospitalizations, and fewer 
surgeries. The treatment to IBD is based in a system where, patients having mild or 
moderate disease receive aminosalicylates and occasionally corticosteroids, for disease 
flares. 
 IBD treatments include aminosalicylates that decrease inflammation, block 
prostaglandins and leukotrienes production, inhibits chemotaxis, scavenges oxygen 
radicals, inhibits Nk-kB, acting by as an agonist of peroxisome prolifetator-activated 
receptor-ϒ (Martins and Peppercorn 2004) (Grimm 2009). Corticosteroids, that provide 
potent anti-inflammatory activity for the induction and remission of UC and CD, 
however they aren't capable of maintaining the remission (fewer than one-third remain 
in remission at 12 months with another quarter becoming steroid dependent and a 
substantial portion requiring surgery), the use of corticosteroids is limited due to its 
adverse effects, and based on that, budesonide was develop as a less toxic corticosteroid 
(Martins and Peppercorn, 2004) (Grimm, 2009). Immunosuppressive medications, the 
most used is azathioprine, it acts inducting apoptosis of T lymphocytes, thereby 
reducing the effector compartment of the ongoing intestinal immune response, this kind 
of treatment is used for maintenance of remission in CD and UC, and it may take up to 
six months to observe any response (Martins and Peppercorn, 2004) (Grimm, 2009). 
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Antibiotics they work by changing   luminal flora and this way diminishing activation 
of the mucosal immune system. (Martins and Peppercorn 2004). The use of single 
antibiotics is likely to be unsuccessful in CD because of the development of bacterial 
resistance (Friswell, Campbell et al. 2010). Anti-TNF-α is a field of treatment that has 
been very explored in past decade, and infliximab (the most used substance in this 
class), is chimeric monoclonal IgG1 antibody against TNF-α, it's 75% human protein 
and 25% murine protein which selectively targets TNF-α. It works by binding 
membrane-bound TNF-α and inducing cell lysis by antibody-dependent cell-mediated 
cytotoxicity or complement fixation and apoptosis. It is now used for maintenance 
therapy in CD and UC (Martins and Peppercorn, 2004) (Cho and Abraham, 2007) 
(Grimm, 2009) (Baumgart and Sandborn, 2007) (Abraham and Cho, 2009) (Neuman 
2007) (Leung and Hanauer, 2009).  
Other potential treatment options consist in the blockage of inflammatory cell 
migration, selective adhesion molecule inhibitors interfere with the migration of 
leukocytes to the site of inflammation by interacting with adhesion molecules. Such as 
natalizumab, which is a recombinant monoclonal antibody against α4 integrin, that 
works by blocking the recruitment of leukocytes (Martins and Peppercorn, 2004) 
(Hanauer, 2006) (Baumgart and Sandborn, 2007) (Neuman, 2007). 
Stem cell transplantation (mesenchymal and hematopoietic cells) are becoming a 
therapeutic option to IBD, since no curative options exist to date, a stem cell-based 
approach could drive a major change in disease management and treatment. A high-
dose immune ablation regimen could allow detrimental T-lymphocyte repertoires to be 
eliminated and after HSC transplantation (HSCT) de-novo hematopoiesis would 
generate naive cells. Patients receiving an autologous HSCT are thought to be subject to 
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an immune system reboot: the genetic defects would not be eliminated but remission 
could persist in the absence of deleterious environmental triggers (Lanzoni, 2008). 
Probiotics have beneficial effect on IBD treatment, with the main related 
mechanisms including: a) inhibiting microbial pathogens growth; b) increasing 
epithelial tight junction and permeability; c) modulating immune response of intestinal 
epithelia and mucosal immune cells; d) secreting antimicrobial products; e) 
decomposing luminal pathogenic antigens. Probiotics compete with microbial 
pathogens for the limited number receptors present on the surface of epithelia, and 
inhibit epithelium attachment and invasion by enterotoxigenic and enteropathogenic 
bacteria (Bai and Ouyang 2006).  
  Reactive Oxygen Species 
Reactive Oxygen Species (ROS) have been largely studied from different 
perspectives, some think they’re bad and cause innumerous diseases, others think 
they’re essential and conserved during our evolution and others think ROS should be 
kept in a very tight control. 
ROS are chemical oxygen species with one or more unpaired electrons that make 
them chemically reactive to other species. ROS include superoxide (•O2
-), the hydroxyl 
radical (•OH), the hydroperoxyl radical (•O2H), nitric oxide (NO•), and singlet oxygen 
(O2) (Wiseman H. et al, 1996) (McKercher S.R. et al, 2009) (Siow Y. et al, 2011) 
(Alzoghaibi M.,2013). In the normal aerobic metabolism oxygen is the last receptor of 
electrons in mitochondrial respiratory chain, being in last term fully reduced to water. A 
small percentage of electrons do not travel to the end of the chain staying free to react 
with O2 and form •O2
- (Wiseman H. et al, 1996) (Finkel T., 2011) (Siow Y. et al, 2011) 
(Alzoghaibi M., 2013). However mitochondria is not the only precursor for ROS there 
are oxidase enzymes like NADPH (see below) in phagocytic cells and arachidonic acid 
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metabolizing enzymes (e.g. cyclooxygenase and lipoxygenase) that also produce 
superoxide that serves as predecessor for other ROS (Alzoghaibi M., 2013) (Kanyilmaz 
S. et al, 2013) (Madamanchi N.R. et al, 2013). Although we cannot forget one of the 
most important reactions that lead to •O2
- , Fenton reaction, in which ferric and cupric 
ions ( Fe3+, Cu2+)  are reduced by superoxide and then react with H2O2  to form •OH . 
(Rada B. et al, 2008) Nitric oxide is synthesized from L-arginine by nitric oxide 
synthase. Those compounds can lead to oxidative damage to a variety of biological 
molecules, like lipids, proteins and nucleic acids (Wiseman H. et al, 1996) (Siow Y. et 
al, 2011)  (Alzoghaibi M.,2013). 
It is proved that among the 44 highly conserved proteins with known functions 
regulate stress response, and 40% of them are related to regulation of the intracellular 
redox status. It is noticed that increased reactive oxygen species (ROS) generation 
seems to be a common response in cells exposed to stresses; thus, it is argued that redox 
regulation may represent a critical second messenger system that is upstream of the cell 
stress signaling network (Jiang F. et al, 2011) (Kanyilmaz S. et al, 2013) ROS may 
influence changes in gene expression both directly, by altering the function of many 
transcription factors, or indirectly by altering (Lambeth J., 2007). 
In fact, the intentional localized production and clearance of these reactive 
molecules by intrinsic enzymes in addition to the observation that redox conditions may 
be genetically pre-determined and evolutionarily significant, suggest that ROS play a 
far more integral role in the regulation of cellular and whole organism health, than was 
previously thought. It is becoming increasingly evident that under physiological 
conditions, ROS participate in crucial cellular events, functioning either directly as 
signaling molecules and/or indirectly by mediating global changes in the cellular redox 
status. Some of their down-stream targets include metalloenzymes and transcription 
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factors that are sensitive to redox changes (Finkel T, 2001) (Lambeth J., 2007) (Chan E. 
et al, 2009) (Jiang F. et al, 2011) (Siow Y. et al, 2011) (Chaubey S. et al, 2013). 
1.4.1 NADPH in ROS production 
Several oxidoreductases have been identified as potential sources of superoxide in 
mammalian cells. These include cyclooxygenase, lipoxygenase, cytochrome P450 
enzymes, nitric-oxide synthase, xanthine oxidase, mitochondrial NADH: ubiquinone 
oxidoreductase (complex I), and nicotinamine adenine dinucleotide phosphate-oxidase 
oxidase. NADPH is a professional ROS producer, its role is only to produce ROS, and it 
is in the cell membrane being constituted by various subunits. In its constitution it has 
cytochrome b558, which consists of two subunits gp91phox (Nox2) and p22phox. Upon 
cell activation, two cytosolic regulatory subunits p47phox and p67phox, as well as two 
small G proteins Rac1 and 2, translocate to the membrane and associate with the 
cytochrome b558 (Wiseman H. et al, 1996) (Hartl D. et al, 2008)  (Chan E. et al, 2009) 
(Jiang F. et al, 2011) (Siow Y. et al, 2011) (Kanyilmaz S. et al,2013). 
This multisubunit enzyme complex then generates superoxide by one-electron 
reduction of oxygen via its gp91phox subunit using reduced NADPH as the electron 
donor. It has been discovered that NADPH is not exclusive for phagocytic cells, other 
isoforms had been discovered, that includes six Nox isoforms (Nox1, -3, -4, -5, and 
Duox1, -2), one p47phox isoform (Nox1) and one p67phox isoform (Noxa1) have been 
identified in mammalian cells and the expression patterns of these isoforms are distinct 
and seem to be tissue-specific (Finkel T, 2001) (Chan E. et al, 2009) (Jiang F. et al, 
2011) (Kanyilmaz S. et al, 2013). 
NADPH oxidase is a distinct enzymatic source of cellular ROS generation, because 
this enzyme is a “professional” ROS producer (Lambeth, 2004), whereas the other 
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enzymes produce ROS only as by-products along with their specific catalytic pathways 
(Jiang F. et al, 2011). 
Several lines of studies have suggested that one important physiological function of 
NADPH oxidase in mammalian cells is the modulation of multiple redox sensitive 
intracellular signaling pathways by generating ROS molecules, including inhibition of 
protein tyrosine phosphatases, activation of certain redox-sensitive transcription factors, 
and modulation of the functions of some ion channels (Bedard and Krause, 2007) (Jiang 
F. et al, 2011). 
Some authors think that certain stimuli like radiation, heavy metals and toxic 
chemicals into leads to cellular stresses and suggest that NADPH oxidase may be an 
important component of the cellular stress signal transduction network. NADPH 
oxidase/ROS-mediated signaling might therefore represent a cellular “alarm system” 
that can alert the cells and prime the cells either to be adapted to the stress or to undergo 
apoptosis being an ancient mechanism of multicellular organisms’ defense (Chan E. et 
al, 2009)  (Lambeth J., 2007) (Kanyilmaz S. et al, 2013). 
So, Nox-mediated redox signaling activation may have a critical role in 
coordinating the responses of the cell to deal with the adverse effects, either by 
activating stress kinases and promoting stress tolerance or by removing the seriously 
damaged cells by inducing apoptosis (Chan E. et al, 2009) (Jiang F. et al, 2011) 
(Kanyilmaz S. et al, 2013). 
 Interestingly, in a study by Krieglstein et al pondered the role of ROS in the 
colonic inflammation using a DSS model of ulcerative colitis. Their findings 
demonstrated that both the genetic absence, by the use of iNOS -/- mice, and 
pharmacologic blockade of iNOS, using an specific iNOS inhibitor(1400W), can 
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significantly attenuate the severity of colonic inflammation from DSS colitis supporting 
a proinflammatory role for iNOS. They also showed that colonic tissue injury and 
inflammation is exacerbated in mice that genetically over-express CuZnSOD compared 
to wild-type controls. They also disclosed that a disrupted NADPH oxidase function, 
through a knockout of p47phox protein, appears to not interfere with the susceptibility 
to DSS-induced intestinal inflammation (Krieglstein, C. et al, 2001). 
In another study by Bao et al the idea of alterations in the NADPH oxidase 
proteins having no influence in the susceptibility in DSS-induced colitis continue, 
where p47phox-/- mice don’t show significant differences when compared with WT mice 
and suggest that gp91phox-/- are less susceptible to an acute DSS-induced colitis  (Bao, C. 
et al,2011). 
Contrastingly, another study has demonstrated that mice lacking the p40phox subunit 
of NADPH are more susceptible to DSS-induced colitis, with an enhanced neutrophil 
infiltration, thus indicating that NADPH oxidase activity can affect and modulate the 
inflammatory response by affecting not only the acute response but also having an 
important role in the resolution and recovery(Conway, G. et al, 2012). 
1.4.2 ROS in tissue and wound repair 
Accumulating evidence suggests that Nox has an important role in signal 
transduction in cellular stress responses, (Jiang F. et al, 2011) (Kanyilmaz S. et al, 
2013) being involved in many other mechanisms than self-defense like cell proliferation 
(Finkel T, 2001) (Chan E. et al, 2009) (Jiang F. et al, 2011) (Chaubey S. et al, 2013) 
(Kanyilmaz S. et al, 2013). There are evidences that NADPH oxidase-derived ROS are 
involved in cell proliferation of vascular cells specifically Nox2, Nox4 and Nox5. There 
are also indications that different isoforms have distinct roles in the regulation of 
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vascular cell proliferation and this may be related to their differential sub-cellular 
compartmentalization. Many studies have shown that Nox activation has a positive role 
in regulating proliferation of collagen-producing cells, including fibroblasts, kidney 
mesangial cells, and stellate cells of the liver and pancreas and in intestinal cells (Chan 
E. et al, 2009) (Chaubey S. et al, 2013) (Kanyilmaz S. et al,2013). 
There are information about wound healing too, revealing that ROS are mainly 
produced before inflammatory leucocyte oxidative burst and the knockdown of Nox 
complexes leaded to educed wound-induced H2O2 production and suppressed the 
consequent recruitment of leukocytes to the wound. These results may indicate that 
ROS may have signaling actions beyond the single cellular context and may play an 
important paracrine signaling role during the wound repair process (Chan E. et al, 2009) 
(Gauron C., 2013) (Kanyilmaz S. et al, 2013). Studies in zebra fish showed that ROS 
are present and essential for wound repair and are not restricted to the first phase of 
wounding but several hours later, initiating numerous signaling pathways (Chan E. et al, 
2009) (Finkel T, 2001) (Gauron C., 2013). 
1.4.3 ROS in Immunity 
Nox2-generated ROS can participate in immune function in a variety of ways, 
which are not mutually exclusive. First, the reactive oxygen itself or its byproducts such 
as HOCl and peroxinitrite can directly oxidize biomolecules in invading microbes in a 
fairly non-specific manner, resulting ultimately in molecular damage and microbial cell 
death. Second, the ROS can participate in signal transduction mechanisms linked to 
immunity and inflammation. This occurs through the selective oxidation of specific 
signaling enzymes/proteins that are linked to processes such as the secretion of 
cytokines or the activation of other killing mechanisms. Such signaling targets include 
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transcription factors such as NFk-B, signaling proteins such as protein kinases and 
phosphatases and ion and/or proton channels (Lambeth J., 2007).  The first role to be 
definitively established for Nox-derived ROS was in innate immunity mediated by 
professional phagocytes such as neutrophils and macrophages. It can be calculated that 
the concentration of ROS produced in the phagosome is extremely high, probably in the 
molar range (Reeves P. et al, 2002) (Lambeth J., 2007). In addition, myeloperoxidase 
(MPO) is secreted into the phagosome where it converts H2O2 plus chloride into HOCl; 
the latter has a direct microbicidal effect (Hampton B., 1998) (Klebanoff J., 2005) 
(Lambeth J., 2007) although surprisingly, MPO-deficient individuals do not suffer from 
markedly increased rates or apparent severity of infections (Lanza F., 1998) (Lambeth 
J., 2007). In addition, macrophages produce large amounts of NO during phagocytosis; 
when NO reacts with superoxide, it generates the highly cytotoxic chemical species 
peroxinitrite (HONO) (Lambeth J., 2007). The activity of the phagocyte NADPH-
oxidase also triggers opening of proton and potassium channels (Reeves P. et al, 2002)  
(Lambeth J., 2007), that are proposed to change the ionic environment of the 
phagosome thereby activating microbicidal proteases and contributing to microbial 
killing (Reeves P. et al, 2002) (Lambeth J., 2007). Regardless of the precise 
mechanisms, it is clear from the inherited CGD that mutations resulting in defects in 
ROS generation by the respiratory burst oxidase are associated with an inability of 
phagocytes to kill bacteria and other microbes (Segal W., 1996) (Lambeth J., 2007), 
convincingly demonstrating a role for the Nox2 system in innate immunity mediated by 
professional phagocytes (Lambeth J., 2007) (McKercher S.R. et al, 2012). 
Neutrophils are the first line of defense with highly efficient bactericidal and 
tissue-toxic mechanisms in host protection including the phagocytosis of opsonized 
particles, degranulation with release proteases and the production of ROS.  Among 
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these functions, production of reactive oxygen intermediates (ROIs), known as 
respiratory burst, is especially important in microorganism killing. Considering that 
efficient phagocytosis and the subsequent production of ROIs play an important role in 
the intracellular killing of microorganisms by phagocytes, defects in one or both of 
these functions may lead to a deficiency in phagocytic function (Pavlik K. LF et al, 
2002) (Rada B. et al, 2008) (McKercher S.R. et al, 2012), 
So, undoubtedly ROS are essential for immune response and for its action 
destroying pathogens, there are opinions that its deregulation leads to Oxidative Stress 
and consequently to disease. However there are examples like CGD where 
dysfunctional ROS production leads to high inflammation levels and many 
complications 
1.4.4 ROS Imbalance 
ROS has to be kept under very straight concentrations, if there is an imbalance 
between ROS production and scavenging we are towards Oxidative Stress. That might 
happen because of antioxidant decrease (e.g. mutations in antioxidant enzymes like 
superoxide dismutase, glutathione peroxidase) and ROS over-production (e.g. excessive 
activation of ROS producers) (Wiseman H. et al, 1996) (Pavlik K. LF et al, 2002) (Siow 
Y. et al, 2011). 
So, this homeostasis is essential to healthy function, but when Oxidative stress 
occurs many things can happen. There is an adaptation to the new condition, increasing 
scavenging mechanisms for example; tissue injury because of lipid peroxidation, DNA 
and protein damage or in last term cell death by apoptosis or necrosis (Wiseman H. et 
al, 1996). 
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ROS can start to interact with DNA, lipids, proteins and so one changing them 
irreversibly and those interactions can lead to diseases like cancer, heart disease and 
many others (Wiseman H. et al, 1996).For example lipids oxidation can occur in the 
presence of free oxygen radicals, taking to hidroperoxides and lipid peroxides 
formation. That is because the double bonds of polyunsaturated fatty acids (PUFA), 
such as linoleic acid, are susceptible to oxidation by ROS. So, losing an electron, lipids 
became radical (L•) and when react with O2 forms a peroxyl radical (LOO•). Lipid 
peroxides and oxygen radicals are responsible for many of the damaging reactions in the 
cell. They stimulate the peroxidation reactions that are toxic to cells and cell 
membranes. They can damage biological membranes, make the membrane leaky, and 
eventually cause complete membrane breakdown (Wiseman H. et al, 1996) (Alzoghaibi 
M., 2013). 
Another redox-sensitive transcription factor is p53. It was demonstrated that 
oxidation of p53 alters its conformation and disrupts its DNA binding activity, resulting 
in a pattern change of p53-dependent gene expression. Moreover, p53 was shown to act 
as a homeostatic regulator by lowering ROS levels in stem cells and controlling 
hematopoietic stem cell self-renewal. Finally, the NF-kB signaling pathway is also 
significantly altered by deregulated ROS. ROS activates NF-kB signaling through 
elimination of the IkB inhibitor (Chan E. et al, 2009) (Siow Y. et al, 2011). An increase 
in ROS levels induces the activation of the IkB kinase (IKK), which in turn 
phosphorylates IkB, leading to its proteasome-dependent degradation (Pavlik K. LF et 
al, 2002) (Madamanchi N.R. et al,2013) (Maryanovich M. et al. 2013). 
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1.4.5 Antioxidants 
Substances or compounds that are able to scavenge oxygen free radicals or 
inhibit their process of formation are called Antioxidants. We can get them from diet 
(ex.: vitamins A, B and C), but we also have our own antioxidants enzymes. Those 
mechanisms exist to counter ROS damages to cells and it should be enough to maintain 
homeostasis. Anyway this balance can be lost when there is over-production of free 
radicals and the nutrients containing antioxidants are not enough (Wiseman H. et al, 
1996) (Rezaie A. et al, 2004). (Finkel T., 2011) (Alzoghaibi M., 2013). 
Antioxidants can be considered plasma antioxidants and intracellular 
antioxidants. The major role of plasma antioxidant defense is to bind transition metal 
ions, such as iron and copper, thereby lowering their plasma concentration and capacity 
to stimulate free radical reactions preventing lips peroxidation. Ascorbic acid (vitamin 
C) for example can scavenge water-soluble peroxyl radicals and other ROS. Vitamin E 
(α-tocopherol) is a lipid peroxidation, chain-breaking antioxidant, localized in 
membranes and lipoproteins (Alzoghaibi M., 2013). 
Regarding intracellular antioxidant enzymes there are superoxide dismutase 
(SOD), glutathione peroxidase (GSHPx), and catalase. (Wiseman H. et al, 1996) 
(Rezaie A. et al, 2004) (Siow Y. et al, 2011) (Alzoghaibi M., 2013) SOD is localized in 
both the cytosol (CuZn-SOD) and mitochondria acting to dismutate superoxides into 
hydrogen peroxide and molecular oxygen. SOD is considered as the major intracellular 
enzyme because it is capable of reducing the most abundant free radical, •O2.Catalase 
reacts rapidly with hydrogen peroxide, a precursor of •OH in the presence of iron, and 
converts it into water and molecular oxygen. Selenium glutathione peroxidase also 
converts hydrogen peroxide into water and lipid hydroperoxides into water and 
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harmless fatty acid alcohols. (Wiseman H. et al, 1996)  (Alzoghaibi M.,2013) The 
mechanisms underlying endothelial dysfunction are multi-factorial with oxidative stress 
playing a major role. The kinetics of the reaction of •O2 with •NO are three times faster 
than there action rate of •O2 with SOD. Thus, it is likely that some •O2 always reacts 
with •NO within the cells and extracellular space, but endogenous antioxidant defenses 
minimize this interaction (Pou S. et al, 1992). 
Finkel T. found that once oxidants are associated to the regulation of crucial 
physiological processes, antioxidants are not merely ROS scavengers but rather exist in 
the cell as sensors and effectors of redox-regulated pathways. It is important to note that 
there is growing evidence that the regulation of antioxidant levels in cells is intimately 
connected with ROS levels and oxidant production sources (Finkel T., 2001) (Finkel T., 
2011). 
1.4.6 ROS in Disease 
Regarding the importance of redox in regulating crucial cellular events, the presence 
of oxidative stress means that there are oxidative perturbations that if not corrected, 
could result in a disease state. Cancer, cardiovascular disease, and metabolic disorders 
such as metabolic syndromes are the leading causes of death worldwide, with the 
number of cases for each condition projected to increase substantially over the next few 
decades. Cancer is an - example of a complete disarray of cellular redox homeostasis. 
Unlike metabolic disorders, both oxidative and reducing cellular environments appear to 
play a role in carcinogenesis. Oxidative imbalances may trigger a multitude of 
molecular and cellular events induced by the ROS (Finkel T, 2001) (Siow Y. et al, 
2011). 
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1.4.6.1 CGD 
Chronic granulomatous disease (CGD) is characterized by NADPH oxidase 
complex inhibition which leads to hyperinflammation, suggesting that the normal 
functions of this complex in macrophages and potentially other inflammatory cells are 
essential in restricting or resolving inflammation (Chaubey S. et al, 2013). 
CGD is the most common inherited disorder of neutrophil function, is caused by 
mutations in NADPH oxidase, and results in recurrent bacterial infections (Hartl D. et 
al, 2008). Phagocytes of patients with CGD are therefore unable to kill ingested 
microorganisms, which results in a concomitant increased susceptibility to bacterial and 
fungal infections (Hartl D. et al, 2008) (Rada B. et al, 2008). Activation of NADPH 
oxidase was found to negatively regulate IL-8 mRNA expression in neutrophils, and the 
absence of NAPDH oxidase in neutrophils from patients with CGD resulted in an 
increase of IL-8 production (Hartl D. et al, 2008). 
Hartl D. et al found that reduced complement receptor expression by neutrophils 
from patients with CGD was associated with impaired bacterial opsonophagocytosis. 
Although further indications exist that neutrophils from patients with CGD display 
impaired phagocytosis (Hartl D. et al, 2008). 
1.4.6.2 Inflammatory Bowel Disease  
Oxidant stress is a major factor in IBD. It’s been described that IBD (UC and 
Crohn’s) patients have an enhanced production of reactive oxygen metabolites by 
epithelial  and phagocytic cells (neutrophils, monocytes and macrophages) that leads to 
an increased oxidative stress in mucosal tissues (Kitahora S. et al, 1988) (Lih-Brody P. 
et al, 1996) (Alzoghaibi, 2013). It’s stated that monocytes and polymorphonuclear cells 
in IBD are activated and produce high levels of pro-inflammatory mediators such as 
leukotriene B4 (LTB4) or platelet activating factor (PAF) leading to the release of large 
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amounts of potentially cytotoxic reactive oxygen metabolites demonstrated through in 
situ quantification and through evaluation of lipid peroxidation (Sharon and Stenson, 
1984) (Kitahora S. et al, 1988) (Almenier A. et al, 2012) (Alzoghaibi, 2013). This was 
also related to the augmented migration of neutrophils and macrophages into the bowel 
mucosa, higher levels of ROS and the degree of inflammation and tissue damage 
(Kitahora, S. et al, 1988) (Alzoghaibi, 2013). It’s been showed that not only there is an 
increased oxidative stress in mucosa but also a decrease of antioxidants, with low blood 
levels of vitamin C and vitamin E, low levels of CuZn superoxide dismutase (SOD), 
glutathione peroxidase, catalase, vitamin A and β-carotene, thus leading to an increased 
oxidative state (Lih-Brody, P. et al, 1996) (Alzoghaibi ,2013). 
Clinical data have shown that the administration of bovine CuZnSOD leads to an 
attenuated mucosal inflammation and injury in Crohn’s patients (Kruidenier, K. et al, 
2003) (Alzoghaibi, 2013). 
It’s also acknowledged that the use of sulfasalazine (SAZ), mostly known by its  
commercial name 5-ASA, is beneficial in Crohn’s disease by inhibiting cyclooxygenase 
and lipoxygenase activities, and interacts with the superoxide, suppressing the 
formation and promoting of the degradation of free radicals, therefore protecting from 
oxidative stress-induced mucosal injury and inflammation (McKenzie, D. et al, 1999) 
(Couto, R. et al, 2010) (Alzoghaibi, 2013). 
Pavlik et al say that besides ROS overproduction, NADPH is not involved in it 
once that inhibiting it made no alteration in the susceptibility of mice to DSS-induced 
colitis, indicating that NADPH oxidase is not involved in the pathophysiology of this 
model of ulcerative colitis (Pavlik K. LF et al, 2002). Leoni G. et al demonstrated that 
epithelial ROS induce a pro-resolution of epithelial wound closure, by mediating 
Anexin 1 (anti-inflammatory protein) production that control excessive immune cell 
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trafficking by many mechanisms, one of them neutrophil influx inhibition and apoptosis 
at resolving inflammation site (Leoni G. et al, 2013).So, the effective role of ROS in 
IBD is still not clear, however a new lines of thought consider that ROS has a resolution 
role in IBD. 
The levels of ROS in both Crohn’s and ulcerative colitis are normally measured 
in an indirect way by the detection of the subproducts of an excessive lipidic 
peroxidation reaction, such as malondialdehyde and 4 hydroxynonenalos (Chiarpotto, S. 
et al, 1997) (Alzoghaibi ,2013). 
Protein damage and peroxynitrite alteration through oxidative damage by 
markers like Carbonyl content in cells/tissues (Lih-Brody, P. et al, 1996) (Chevion, B. 
et al, 2000) and residues of 3-nitrotyROSine (Ischiropoulos and al-Mehdi, 1995) 
(Singer, K. et al, 1996) have also been observed in both Crohn’s disease and ulcerative 
colitis. 
Inflammation is associated with the production of ROS as a probable cause of 
neoplasic evolution (Marnett, 2000). ROS is being reported to be a cause of DNA 
alterations through the augmentation of 8-hydroxyguanine (8-OHDG) production in 
Crohn’s disease (Lih-Brody, P. et al, 1996). In another study by D’Inca et al on 
ulcerative colitis, the high levels of 8-OHDG correlated with higher levels of ROS lead 
to an accumulation of oxidative DNA damage alongside with the progression of the 
disease and correlates with higher dysplastic lesions and  possible implications for 
mutagenic and carcinogenic progression (D'Inca, C. et al ,2004). 
Interestingly, the complete absence of ROS also seems to be problematic. 
Indeed, it is a characteristic of Chronic granulomatous disease (CGD), an heterogeneous 
primary immunodeficiency disorder characterized by a defect in Nicotinamide adenine 
dinucleotide phosphate (NADPH) - oxidase (Nox) complex (characterized by the 
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presence of X-linked mutations on gp91phox gene (65%), autosomal recessive forms: 
p47phox (30%), p67phox (<5%) or p22phox (<5%)),  leading to a deficit in the production of 
oxygen free radicals in specialized phagocytic cells (neutrophils , monocytes, 
macrophages) and other cells, such as eosinophils and lymphocytes. Thus, patients with 
CGD develop severe systemic infections and/or granuloma formation through recurrent 
bacterial infections with positive catalase, Staphylococcus spp, Salmonella spp, 
Pseudomonas spp, Mycobacterium spp, Nocardia spp, and Burkholderia cepacia among 
others, and fungi such as Candida albicans and Aspergillus spp. Such infections result 
in the formation of chronic granulomas, composed of clusters of inflammatory 
monocytes and macrophages unable to effectively engulf infectious agents, and lead to a 
high incidence of mucosal inflammatory disorders (such as chronic colitis) (Al-
Mobaireek 2001) (Noack, R. et al, 2001) (Sartor, 2006) (Towbin and Chaves, 2010) 
(Song, J. et al. 2011). 
 It’s already being demonstrated that IBD patients can have a defective 
neutrophil respiratory burst (Segal and Loewi, 1976) (Verspaget, M. et al, 1984). But 
despite early reports from genome-wide association studies (GWAS) indicating the 
NCF4 gene as susceptibility gene for CD (Rioux, X. et al, 2007) (Roberts, H. et al. 
2008) a recent GWAS study didn’t corroborate these results (Franke M. et al, 2010). 
Even so, in a study by Muise et al they not only replicate the association of 
NCF4 with CD previously described but also illustrated a novel associations of the 
NADPH oxidase complex gene RAC2 with CD and introducing a novel missense 
variant in NCF2 with very early onset IBD that leads to an neutrophil dysfunction and 
susceptibility to CD, thus indicating that the NADPH oxidase complex genes play a role 
in the pathogenesis of CD (Muise, X. et al, 2012). 
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 Objectives 
 
The main objective of this study was to understand the role of ROS in an 
immunological response in a situation of DSS- induced colitis. 
To achieve this goal we proposed to: 
- Evaluate physical mice evolution during the experiment; 
- Evaluate the immune populations behavior in the presence and absence of ROS; 
- Evaluate histological intervention of DSS in both strains; 
- Evaluate the effects of ROS absence in the progression of the disease.
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2 Methods 
 Animals 
6-8 weeks old male or female homozygous Ncf1-mutant (BQ.Ncf1m1J/m1J, 
abbreviated Ncf1, n=30) and wild-type (WT, n=30) B10.Q mice were obtained from 
breeding heterozygous mice followed by genotyping, as previously described 
(Gelderman H. et al, 2006). Animals were bred and maintained under standard 
conditions, with food and water ad libitum in a specific pathogen–free environment. All 
animal studies were approved by the internal CNC Ethics Committee, and were in 
accordance with EU legislation for experimental animal welfare Induction of colitis 
 Induction of colitis 
Colitis was induced by oral administration of 3% (w/v) DSS (average 40,000 g/mol, 
AppliChem, Darmstadt, Germany) in the first induction cycle and 2.5% (w/v) DSS in 
the second cycle ad libitum in drinking water. Reduction of DSS concentration was to 
avoid premature death. Two different colitis-induction protocols were used (Fig 1): 
Experiment 1 (E1) - mice were submitted to 7 days DSS-induction followed by 21 days 
of resting on normal water. Experiment 2 (E2) - mice were submitted to 7 days of DSS-
induction, followed by 14 days of resting on normal water and a second 7 days DSS-
cycle. Five Ncf1 and WT mice were sacrificed at the end of each time point: before the 
experiment had started and at days 22 and 30. Tissues were collected for 
histopathological analysis and assessment of colon length and spleen weight. 
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Figure 1 Schematic representation of the two experimental protocols. E1) Experiment 1: One 
week DSS induction and 3 weeks recovery.  E2) Experiment 2: one week DSS induction, 2 
weeks recovery and another week DSS induction.   Indicate the time-points when mice were 
sacrificed. 
 
 Clinical Evaluation 
The clinical scores of colitis: weight change, diarrhea, colorectal bleeding and 
survival were monitored every other day. Blood scoring: 0- no blood; 1- visible blood; 
2- rectal bleeding. Consistency scoring: 0- Normal; 1- Soft but formed; 3- very soft; 4- 
diarrhea.  
 Flow Citometry 
Lymph nodes samples were collected from the base of the tail from all mice on 
days 0, 22 and 30. Mononuclear cells were stained in a standard method (Raposo et al, 
2010) using Fluorescein isothiocyanate (FITC), R-Phycoerythrin (PE), Aloficocianina 
(APC), Aloficocianina-cyanine 7 (APC/Cy7), Phycoerythrin-cyanine 7 (PE/Cy7), 
Peridinin chlorophyll protein-cyanine 5.5 (PerCpCy5.5) and Pacific Blue, with 
conjugated anti-mouse monoclonal antibodies (mAb) surface markers: CD1d, CD3, 
CD4, CD5, CD8, CD11b, CD19, CD21, CD23, CD27, CD43, CD49b, CD62L, FoxP3, 
Ly-6c and IgM,NK1.1 (all from Biolegend). 
Day 22 
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Day 0 
Recovery 
Day 30 
 
Recovery Recovery 
  
Day 0  
DSS Recovery Recovery DSS 
Day 30 
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 
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E1 
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Intracellular staining using anti-mouse mAb was done after saponin 
permeabilization: CD25 and iL10 (all from Biolegend). 
All samples were analyzed on a BD FACSCanto II (Becton Dickinson) and data 
were analyzed with FlowJo 7.6.4 software (Tree Star). 
 Histopathological evaluation of colitis 
Separate swiss rolls of distal and proximal colon were fixed in 4% neutral 
buffered formalin, paraffin embedded and stained with hematoxylin/eosin (HE) 
according to standard protocols. 
Inflammation was scored for each colon section according to the number of 
inflammatory foci present: 0- no inflammatory focus; 1- one inflammatory focus; 2- two 
inflammatory foci; 3- three or more inflammatory foci. Dysplasia was scored for each 
colon section using a semi-quantitative scale: 0- no dysplasia; 1- hypercromatic nuclear 
pluristratification and lamina propria separated  glands; 2- epithelial low grade 
dysplasia :complex ramified glands with cell hyperplasia and pluristratified 
hypercromatic nuclei , 3- epithelial high grade dysplasia :beyond low grade dysplasia, 
nuclear atypia and mitosis.  
 Statistical Analysis 
All data were tested for normal distribution with Levene´s test. Since data did 
not follow a normal distribution the non-parametric Kruskal-Wallis test followed by a 
non-parametric Mann-Whitney test were used to compare values between groups and 
time-points, using Statview 5.0.1 software (SAS Institute Inc, USA). Statistical 
differences between curves were determined using a 2-sided hypothesis permutation test 
with 10000 permutations (http://bioinf.wehi.edu.au/software/russell/perm/). Differences 
were considered significant for p <0, 05.  
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3 Results 
 Clinical Signs of DSS-induced colitis 
In both protocols the two mouse groups presented a significant reduction of 
colon’s length after colitis induction (WT: D0 vs D22 p= 0.0159; Ncf1*: D0 vs D22 p= 
0.0102). The length of the colon in both groups of P1 mice at day 30 remained 
equivalent to day 22, whereas WT mice following E2 presented a further significant 
reduction of the colon (p= 0.0025). Mice that were submitted to second DSS-cycle had 
significantly shorter colons than those which were allowed to rest after the first colitis 
induction (WT D30 E1 vs E2 p= 0.0281; Ncf1* D30 E1 vs E2 p= 0.0229) (Fig 2A). 
 At baseline Ncf1* mice presented a significant splenomegaly when compared to 
WT mice (p=0.0139). At day 22 there was a significant increase in spleen's weight in 
both groups when compared to baseline. Moreover, the Ncf1* mice had significantly 
heavier spleens than WT (p<0.0195). At day 30, regardless of protocol, both mice 
groups kept the high spleen weight as at day 22 (Fig 2B). 
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Figure 2 On left colon’s length in centimeters, for days 0, 22 and 30.Spleen’s weight in grams 
for days 0, 22 and 30. Asterisks indicate p<0.05, Mann-Whitney test between Ncf1* and WT 
and Ncf1* Rec and WT Rec. 
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Throughout all study weight was monitored and   Ncf1* presented significantly 
more weight than WT. On day 3, all groups started to lose weight, except controls,  
On day 13, Ncf1* lost significantly more weight than WT (p<0,001), that 
continued until day 22, (p<0,001).  In E2 from 22nd to 30th days, both WT and Ncf1* 
lost weight again, but the weight loss was significant higher in Ncf1*, reaching the 
decrease 80% (p<0.05) of baseline weight (WT=29.8±3.90g, Ncf1*=31.3±3.9g) 
comparing to WT.   
Ncf1*and Ncf1* Rec showed significant weight loss (p<0.0001) than WT. On 
day 13, after DSS treatment WT Rec and Ncf1* Rec presented maximum and 
significant (p<0.0016) weight loss with Ncf1* reaching 25% of baseline weights 
(WT=29.8±3.90g, Ncf1*=31.3±3.9g). By the end of the experiment WT mice weight 
gain was close to the original, while Ncf1* didn't go above 90% of the original weight 
(WT=29.8±3.90g, Ncf1*=31.3±3.9g). 
The presence of blood in stools and the consistency of the feces are two further 
clinical signs of DSS-induced colitis (Rodrigues et al, 2014).  During the 1st induction 
(D0-D7), both Ncf1* and WT groups had an accentuated decrease in stool consistency 
with worse results for Ncf1* group. In both experiments, after 1st induction, all groups 
started to recover with better recovery for WT group. After the 2nd induction (E2) both 
WT and Ncf1*decreased stool consistency and recovery groups got to basal scores (Fig. 
3B). In both experiments Ncf1* and WT groups had similar scores of blood in feces. In 
E2 after 2nd induction (day 22), both groups increased scores showing Ncf1* a more 
accentuated increase. WT recovered better than Ncf1* in the three weeks resting period.  
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Figure 3 A) Mice weights distributions and analysis for the all experiment.in experiment, 
average weight ± SE, (baseline weight: WT=29.8±3.90g, Ncf1*=31.3±3.9g). Asterisks indicate 
p<0.05, double asterisk p<0.001, triple asterisk p<0.0001 Mann-Whitney test between each 
group Ncf1*control/WT control; Ncf1*/WT; Ncf1* Rec/WT Rec; Ncf1*/Ncf1* Rec. B) Mice 
stool consistency. C) Analysis of rectal blood presence. Weight, stool consistency and blood 
presence scorings are detailed in methods section.  
 
WEIGHT
0 5 10 15 20 25 30 35
60
70
80
90
100
110
Ncf1* Control
WT Control
Ncf1*
WT
Ncf1* Rec
WT Rec
***
***
** *** ** *** *** ***
* * ****
STOOL
0 5 10 15 20 25 30 35
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Ncf1*
WT
Ncf1* Rec
WT Rec
BLOOD
0 5 10 15 20 25 30 35
0.0
0.5
1.0
1.5
2.0
Ncf1*
WT
Ncf1* Rec
WT Rec
A
C
B
Chapter 2 – Results 
 
43 
 
 Histology 
The assessment of colon histopathology score was done in untreated WT and 
Ncf1* animals, and after colitis induction at days 22 and 30 for E1 and at day 30 for E2, 
to evaluate dysplasia, epithelial morphology and inflammation, according to the 
described scoring criteria.  
 At baseline WT mice had well designed glands above muscuralis mucosae, 
whereas Ncf1* mice showed a reduced number of glandular tubules (Fig 4). 
 On day 22 E1 WT mice maintained preserved epithelial morphology and villous 
projections plus low grade inflammatory reactive dysplasia. The Ncf1* group presented 
villous projections formed by compacted glands with less vascularization in the pedicle, 
plus glandular high grade dysplasia and invasive tubular adenocarcinoma foci (Fig 4). 
 On day 30 the mice in E1 had reparative villous and glandular adaptation. WT 
mice maintained villous projections corresponding to half of the mucosae length, 
supported by tubular/glandular hyperplasia above the muscularis mucosae, with 
different sizes and segments of very small glands with low grade dysplasia foci. In 
Ncf1* mice colon there was a reduced number of glands under villous projections, 
although there persisted a morphology similar to day 22. In general Ncf1* mice showed 
high grade dysplasia (with anisocariosis with persistent nucleoli and visible mitosis) and 
foci of invasive tubular adenocarcinoma while WT colon presented basal glands’ 
hyperplasia with low grade and high grade segments of dysplasia (Fig 4). 
On day 30 of E2, colonic sections showed persistent adaptation (Fig 4): Ncf1* 
proximal and distal colonic segments kept a glandular morphology with hypercromatic 
nuclei and mucosa-associated lymphoid tissue hyperplasia; and WT colon presented 
epithelial villous projections without inflammation. In distal segments, high grade 
dysplasia persisted in both groups. Additionally, Ncf1* colon developed invasive well-
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differentiated adenocarcinoma in segments where few reserve micro-glands were visible 
above mucularis mucosae, invading till the muscular propria (Fig 4). 
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Figure 4 Colonic mucosa of control Experiment 1and 2, WT and Ncf1*mice groups (H&E 40x, 
100x, 200x). 
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In general histopathological morphology descriptions had more inflammatory 
foci and glandular/epithelial alterations in the distal halves of colonic segments, 
summarized as follows:  
In distal segment of the colon we observed higher inflammation and dysplasia 
scores for Ncf1* mutated mice than WT with statistical significance (p=0.259 for 
inflammation and p=0.0135 for dysplasia), for both strains (Fig. 5A e 5B). Looking for 
recovery, WT recuperated better than Ncf1*. 
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Figure 5. Histological evaluation of inflammation and dysplasia at distal level of the colon for 
Ncf1* mutated mice, Ncf1* Recovery, WT and WT recovery. Asterisks indicate p<0.05, Mann-
Whitney test between Ncf1* and WT and Ncf1* Rec and WT Rec. Inflammation and dysplasia 
scoring system is detailed in the methods section. 
 
At the proximal part of the colon inflammation was higher in both Ncf1* and 
Ncf1* recovery, having WT lower scores than Ncf1* Rec, with statistical significance 
between WT and Ncf1* groups (p=0.0357) after the second induction (Fig. 6A e 6B). 
Considering dysplasia, after the second induction, WT and WT Rec presented higher 
scores than Ncf1* than Ncf*1 Rec respectively with statistical significance between WT 
and Ncf1* groups (p=0.0463).   
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Figure 6 Histological evaluation of inflammation and dysplasia at proximal levels of the colon 
for Ncf1* mutated mice, Ncf1* Recovery, WT and WT recovery. Asterisks indicate p<0.05, 
Mann-Whitney test between Ncf1* and WT and Ncf1* Rec and WT Rec. Inflammation and 
dysplasia scoring system is detailed in the methods section. 
 
 Characterization immune populations in mesenteric lymph node 
Changes in functional frequency of different functional subsets of T cells (CD4+ 
and CD8+), NK cells, B cells and monocytes, subsets were analyzed in the mesenteric 
lymph node since it is the main draining lymph node of the colon  
3.3.1 Macrophages  
Macrophages (CD11b+) showed high frequency at D0 for both experiments 
followed by a decrease for WT and WT recovery groups during all experiment. At day 
23 Ncf1* group had significantly increased levels of this cellular type (p=0.0140), 
comparing with WT. Recovery groups maintained decreased frequency (Fig.7A).Pro-
Inflammatory Macrophages (CD43+/Ly6C+) presented increased frequency in Ncf1* 
groups after day 0. In days 22 and 30 Ncf1* groups showed significant higher 
frequencies (p=0.0079 and p=0.0140 respectively) comparing to WT groups. The 
tendency remained for recovery groups, however with no statistical significance 
between groups (Fig. 7 B). 
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Figure 7 Analysis of mesenteric lymph nodes functional macrophage subsets at the different 
phases of DSS-colitis induction of Ncf1*, Ncf1* Rec, WT and WT Rec mice. Asterisks indicate 
p<0.05, Mann-Whitney test between Ncf1 and WT and Ncf1 Rec and WT Rec. 
 
3.3.2 NK Cells 
Frequencies of NK classic (NK1.1+/CD3-) showed higher for E2 with statistical 
significance (p=0.0101) for Ncf1* group, at day 30 comparing to WT. Ncf1* rec and 
WT rec groups showed decreasing frequencies during recovery after one induction (Fig. 
9A). 
NK expression(NKG2D median), showed increased for both experiments, 
except in the recovery groups where NK cells were more expressed in WT group with 
statistical significance (p=0.0159), when compared to Ncf1* (Fig. 8B). 
NK activated (CD314+/NK1.1+) cells presented decreased during both 
experiments but in day 30, after the second induction, Ncf1* group had increased levels 
comparing to WT with statistical significance (p=0.0303) (Fig. 8C). 
NK immature cells (CD11b-/CD27-) showed an increased frequency in the end 
of both experiments. In day 22 WT increased the recruitment of NK cells with statistical 
significance (p=0.0303) comparing to Ncf1*, recovery groups Ncf1* rec presented 
significant (p=0.0159) increased recruitment of NK cells comparing to WT (Fig. 8D).  
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Figure 8 Analysis of mesenteric lymph nodes functional NK cells subsets at the different 
phases of DSS-colitis induction of Ncf1*, Ncf1* Rec, WT and WT Rec mice. Asterisks indicate 
p<0.05, Mann-Whitney test between Ncf1 and WT and Ncf1 Rec and WT Rec. 
 
Citotoxic NK cells (CD11b+/CD27-) showed decreasing tendency in frequency 
for WT groups. At day 30, WT had a significant (p=0.0177) decrease in NK cells 
frequency comparing with Ncf1*, recovery groups showed the opposite from previous 
groups with significant (p=0.0268) increased frequency for WT comparing to Ncf1* 
(Fig. 9A).  
NK regulatory (CD11b+/CD27+) cells distribution presented higher frequency 
for WT group in both experiments having statistical significance (p=0.0159) in recovery 
groups (Fig. 9B). NK T cells (CD3+/NK1.1+) presented higher frequencies for WT 
groups during both experiments. However, at the end of both experiments, Ncf1* 
showed higher frequencies than WT both in Ncf1*/WT and Ncf1* rec/WT rec showing 
the last statistical significance (p=0.0159) (Fig. 9C). 
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Figure 9 Analysis of mesenteric lymph nodes functional NK cells subsets at the different 
phases of DSS-colitis induction of Ncf1*, Ncf1* Rec, WT and WT Rec mice. Asterisks indicate 
p<0.05, Mann-Whitney test between Ncf1 and WT and Ncf1 Rec and WT Rec. 
 
3.3.3 B Cells 
B lymphocytes (CD19+) frequency was generally higher in Ncf1* mice than WT 
which was seen during almost all experiment. In day 22 we saw statistical significance 
(p=0.0159) between Ncf1* and WT groups and at the end of experiment, day30, Ncf1* 
rec and WT rec show similar frequencies with a recover for Ncf1* comparing to day 22 
(Fig.10A). 
IL10 (iL10) expression in B cells, was higher for Ncf1* group inday0 and at day 
22, IL10 production was low for all groups, increasing after second induction. At day 30 
Ncf1* group had higher levels of expression comparing to WT, with statistical 
significance (p=0.0289) between both groups (Fig.10B). The B1b (CD5+/IgM-) subset of 
B cells presented at days 0 and 22 similar frequencies for both Ncf1* and WT, in day22 
WT had an increase of B1b cells comparing to Ncf1* with statistical significance 
(p=0.0401) (Fig.10C). Ncf1*rec and WT rec groups showed high frequency for WT, 
however there were no statistical significance (Fig.10C). 
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Transitional 3B (CD21+/CD23+) cells population is increased in WT in day 0, 
then it increased again for the same group in day 30 with statistical significance 
(p=0.0077 ) when compared to Ncf1* mice maintaining similar values in other time 
points (Fig.10D). 
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Figure 10 Analysis of mesenteric lymph nodes functional B cells subsets at the different phases 
of DSS-colitis induction for Ncf1*; Ncf1* Rec, WT and WT Rec mice. Asterisks indicate 
p<0.05, Mann-Whitney test between Ncf1* and WT and Ncf1* Rec and WT Rec. 
 
CD3+ T cells presented high frequencies in WT during both experiments with 
statistical significance (p=0.0022) at day 22. Ncf1* rec showed almost the same 
frequency that WT rec which increased since 1st induction (Fig. 11A). 
CD4+ T cells showed at day 0 higher frequency for Ncf1* mice but after the first 
induction all groups showed similar values. After the second induction (day 22) the WT 
group presented a significant (p=0.0262) higher frequency comparing to Ncf1* group. 
Chapter 2 – Results 
 
52 
 
In WT rec and Ncf1* rec counterparts the scores decreased considering 1st induction 
(day 0 - day 7) frequency (Fig. 11B). 
CD4 effector cells (CD62L-/CD27+) presented an increasing frequency for both 
experiments with statistical significance (p=0.0159) at day 22 for Ncf1* group. At day 
30, Ncf1* had their frequency increased compared to WT but with no statistical 
significance (Fig. 11C).  
Naïve CD4 cells (Foxp3-/CD25-) presented a decrease in Ncf1* groups during 
experiment. WT groups showed an increase in this cell population at day 22 followed 
by a decrease at the end of both experiments for WT and WT rec. At day 30 Ncf1* 
presented a significant (p=0.0043) higher frequency comparing to WT (Fig. 11D).  
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Figure 11 Analysis of mesenteric lymph nodes functional T cells subsets at the different phases 
of DSS-colitis induction for Ncf1*; Ncf1* Rec, WT and WT Rec mice. Asterisks indicate 
p<0.05, Mann-Whitney test between Ncf1* and WT and Ncf1* Rec and WT Rec. 
 
T Regulatory 1 cells (Foxp3+/CD25-) presented initially (D0) a higher frequency 
in WT comparing with Ncf1*. There is a decrease in initial frequencies at day 22, at day 
30 this population was significantly (p=0.0260) higher in WT group (Fig. 12A).  
 In all groups T Regulatory 2 cells (Foxp3+/CD25-) presented a decrease 
comparing to day 0 an at day 30, WT had a significantly (p=0.0260) higher frequency 
comparing with Ncf1*. Recovery groups showed increased values for WT comparing 
with Ncf1* not with no statistical significance (Fig. 12B). 
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Figure 12 Analysis of mesenteric lymph nodes functional T cells subsets at the different phases 
of DSS-colitis induction for Ncf1*; Ncf1* Rec, WT and WT Rec mice. Asterisks indicate 
p<0.05, Mann-Whitney test between Ncf1 and WT and Ncf1 Rec and WT Rec. 
 
Central Memory T (CD62L+/CD27+) cells presented an increase frequency for 
all from day 0 to 22, followed by a decrease at day 30 for both groups with no statistical 
significance. . WT rec showed higher values than Ncf1* rec with statistical significance 
(p=0.0159) (Fig. 13A).  
Effector memory T cells (CD62L-/CD27+) exhibited increased frequencies 
during all experiment. Comparing Ncf1* and WT groups at day 30, WT show 
significant (p=0.0022) augmented values comparing with Ncf1* group (Fig. 13B).    
Short-term effector memory T cells (CD62L-/CD27+) showed a significant 
(p=0.0317) decrease of frequency for WT group after 1st induction (D22) comparing to 
Ncf1* group and after 2nd induction (D30) the differences remained significant (p= 
0.0152) with Ncf1* presenting even higher frequency of this cells comparing with 
Ncf1* and with D22 (no statistical significance). In recovery groups Ncf1*presented 
higher scores comparing with WT with no statistical significance (Fig. 12C). 
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Figure 13 Analysis of mesenteric lymph nodes functional T cells subsets at the different phases 
of DSS-colitis induction for Ncf1*; Ncf1* Rec, WT and WT Rec mice. Asterisks indicate 
p<0.05, Mann-Whitney test between Ncf1 and WT and Ncf1 Rec and WT Rec. 
 
 
Central memmory
D
0 
N
cf
1*
D
0 
W
T
D
22
 N
cf
1*
D
22
 W
T
D
30
 N
cf
1*
D
30
 W
T
N
cf
1*
 R
ec
W
T 
R
ec
 
0
20
40
60
80
*
A
Effector memory
D
0 
N
cf
1*
D
0 
W
T
D
22
 N
cf
1*
D
22
 W
T
D
30
 N
cf
1*
D
30
 W
T
N
cf
1*
 R
ec
W
T 
R
ec
 
0
20
40
60
80
100
**
B
Short-term effectors
D
0 
N
cf
1*
D
0 
W
T
D
22
 N
cf
1*
D
22
 W
T
D
30
 N
cf
1*
D
30
 W
T
N
cf
1*
 R
ec
W
T 
R
ec
 
0
10
20
30
40
*
*
C
  
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
DISCUSSION AND CONCLUSION 
 
 
 
 
 
Chapter 3 – Discussion and Conclusion 
 
56 
 
4 Discussion and Conclusion 
The DSS-colitis model is commonly used because of its easy administration and 
its rapid action causing inflammation that -depending on the number of cycles- can 
become chronic and lead to dysplasia (Sugimura, 2000) (Tanaka S. et al, 2005) (De 
Robertis M. et al,2011). 
Using the DSS-colitis model in Ncf1* mice we tried to understand whether the 
absence of ROS has a protective or pathologic role in the chronicity of colon’s 
inflammation. We already knew, from a previous study, that during the acute phase of 
colitis ROS are essential to inflammation’s resolution, since they seem to control the 
exacerbated colonic expression of iNOS and regulate the production of several pro-
inflammatory cytokines by infiltrating leukocytes (Rodrigues-Sousa T. et al. 2014). 
However, the role of ROS in chronic inflammation was not fully addressed. Thus we 
performed two experiments in order to see its involvement in the resolution and 
recovery of an inflammatory process, E1, and on a chronic bowel inflammation, E2 
(two DSS inductions). We found out that Ncf1* mutated mice presented a more 
exuberant response to DSS-induced colitis showing severer clinical scores, high grade 
dysplasia and inflammation with an aberrant immunological response. 
The shortening of the bowel is caused by the mucosa destruction leading to a 
diminished absorption and consequent loss of weight (Gaudio et al, 1990) (Cooper et al, 
1993) (Krieglstein et al, 2001). It is notable that, even though both groups had 
comparable shortening of the colon, Ncf1* mice present a worst recovery of weight in 
both experiments probably because of a diminished capacity to recover from treatment 
(Conway et al, 2012) (Sann, H. et al, 2013). Spleen’s weight is representative of the 
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intensity of the inflammatory response (Axelsson L., 1996). Ncf1* present higher 
scores which represents a more intense inflammatory response. Those alterations in 
mucosa function lead to alterations in feces that start to be less solid with the 
progression of treatments and because of the severity of treatment leads to the presence 
of blood in the stools. (Conway et al, 2012) (Sann, H. et al, 2013). Ncf1* and WT had 
similar scores for feces consistency but the first showed more blood in feces after two 
DSS inductions, result of a more intense response to aggression. (Conway et al, 2012) 
(Sann, H. et al, 2013).  As expected, Ncf1* had a more aberrant response to DSS 
induced colitis with more tendency to dysplasia. In the first experiment Ncf1* mice 
recovery is not as pronounced has in WT mice. In the second experiment Ncf1* show a 
more pronounced inflammation. The alterations in mucosa are evident on histology 
where Ncf1* mutated mice show higher scores of inflammation and increased tendency 
to dysplasia in both experiments. Ncf1* show a decreased capacity to solve 
inflammation and at least avoid dysplasia Sturlan S. et al. showed that IL-10 -/- mice 
spontaneously develop colitis which  leads to high grade dysplasia's which indicates that 
with immune response compromised the propensity for dysplasia increases (Sturlan, 
Oberhuber et al, 2001) (Mino-Kenudson K. et al , 2011).  
We faced some technical obstacles with the analysis of mesenteric lymph nodes 
since mesenteric it is vestigial in the absence of an immune response. Thus it was very 
difficult to find this organ in the necropsy of baseline controls, resulting in low number 
of retrieved cells. On the other hand, the mesenteric lymph node is not frequently 
studied, hence there is little information about the existing leukocyte subsets. Therefore, 
we have discussed the results on mesentheric subsets, by directly comparing to other 
lymph nodes and peripheral blood.  
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ROS influence the immune response to inflammation, leading to an altered 
behavior of immune system in the absence of it. (Kraaij M. et al 2010) (Conway et al, 
2012) (Zigmond E. et al, 2012) (Rodrigues-Sousa T. et al. 2014). Krieglstein et al said 
that Ncf1* (p47phox) mutation has no significance in colitis resolution however he did 
not add a resting period to study ROS role in recovery. Conway et al showed that 
inhibiting Ncf4* (p40phox) subunit of NADPH mice lead to worse recovery from colitis 
similar to the one we have seen for Ncf1 subunit mutation (Conway et al, 2012) 
(Rodrigues-Sousa et al, 2014). 
Macrophages presented increased frequency in Ncf1* after 2 inductions. 
Conway et al had seen a higher pathogen infiltrate, once Ncf1* macrophages have ROS 
production compromised they are not capable to response to that infiltration. However 
they cannot phagocyte, they continue to be produced and recruited so that might be the 
reason why Ncf1* present those values after second induction (Conway et al, 2012). 
Pro-inflammatory macrophages present higher frequency in Ncf1* compared to WT and 
this tendency maintains in Ncf1* rec comparing to WT rec (no statistical significance). 
That is a sign of chronicity, once Ncf1*can’t solve inflammation, pro-inflammatory 
cells keep being recruited to a pro-inflammatory response (Valledor A. et al, 2010). 
The NK population has an important role in tissue inflammation in situations 
like IBD (Schleinitz N., 2010) (Yadav P., 2011). The balance between activation and 
inhibition should be maintained very tight in this population otherwise its cytotoxicity 
might be superior to its regulatory capacity. According to Schleinitz, NK should be 
below normal in IBD situation, but the fact is that NK populations were increased in 
Ncf1* mutated mice and that according to the same author might be due to 
proinflammatory cytokines that hipper activate NK cells promoting inflammation 
(Schleinitz N., 2010) (Yadav P., 2011). Considering NK cells tumor recognizers and 
Chapter 3 – Discussion and Conclusion 
 
59 
 
killers, this increase might be associated with increased levels of dysplasia in the colon 
WT mice show higher frequency of NK activation and NK regulatory which might be 
due an early response to dysplasia from WT groups (Tallerico R. et al, 2013) (Betten 
A., 2004) (Tallerico R. et al, 2013). 
B lymphocytes use to be more activated in IBD usually because of pathogens 
infiltration in the bowel (Brandtzaeg P. et al, 2006). Moreover, Ncf1* mice are more 
prone to opportunistic bacterial infections (Pizolla et al, 2012). The higher frequency of 
mesenteric B lymphocytes in Ncf1* mice, from the beginning of the experiment, 
especially in day 22, might be due to a higher bacterial infiltration and consequently 
more need of lymphocytes activity. Even though we tried to assess the bacterial load 
and phylogeny in the treated animals, we did not get any conclusive results. Since WT 
mice keep an intact anti-bacterial response, the infiltration of B lymphocytes does not 
occur. However, as commonly observed in inflammatory processes (Sims G. et al, 
2005), the frequency of B1b and transitional B cells was higher in WT mice.  
IL-10 downregulates the production of pro-inflammatory cytokines and it is 
overexpressed in IBD (Mitsuyama K. et al, 2006) (Kucharzik et al, 1995). Having in 
account that patients with mutated IL-10 signaling systems show early and aggressive 
development of systemic inflammation including IBD and that Ncf1* showed 
augmented levels of IL-10 cytokine production that might be due to an aberrant 
response of these mice  (Kanneganti, Mino-Kenudson et al, 2011). 
CD3+ and CD4+ T cell populations were overexpressed in WT mice after 2 
DSS inductions which is consistent with Treg 1 and 2 results which are overexpressed 
for WT at D30. T regulatory cells are normally overexpressed in a colitis situation, due 
to damage in gastrointestinal tract leading to inflammation and consequently to T- cell 
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activation (Kraaij M. et al, 2010) (Funderburg N. et al, 2013). Since T regulatory cells 
show an important anti-inflammatory action, their higher frequency in WT comparing 
to Ncf1* show a better response from WT to inflammation (Maul J. et al, 2005). 
CD4+ effectors were higher after 1 DSS induction and CD4+ naïve after 2 DSS 
inductions in Ncf1*. These subsets have been implicated in promoting IBD, 
hencesuggesting a worse response to IBD from Ncf1* mice. (Martin B et al, 2004). 
Short term effectors were increased for Ncf1* at D22 and D30 which represented a pro-
inflammatory response instead of a resolution attempt (Caprioli et al, 2013) 
Central memory  and effector memory CD8+ T cells presented high for WT Rec 
and WT in E2 (2 DSS inductions) indicating that WT were trying to respond better to 
situation that had previous been exposed to. Getting more memory cells implicates a 
faster response to o next induction (Sheridan B. et al, 2011).  
ROS act in many other celluar pathways such as wound repair mechanisms 
(Chan E. et al, 2009) (Gauron C., 2013) (Kanyilmaz S. et al, 2013) so this might 
explain why Ncf1* mutated mice presented more difficulties in recovering from DSS 
abrasion of the mucosa and had severer phisical signs like more blood in feces and 
worse histological scores.  
NADPH oxidase is a ROS producer, it was previous said that ROS should be 
kept in a tight balance since overproduction is dangerous. Here we prove that ROS 
deficiency is equally harmful. Ncf1* mice have their NADPH p47phox subunit mutated 
and their ROS production compromised. As shown in a previous study by Rodrigues-
Sousa T. et al. Ncf1* mice do not produce ROS as that observed in their counterpart 
WT mice. It was also shown by a nitrotyrosine immune fluorescence assay, Ncf1* colon 
produce peroxynitrites in order to balance the absence of ROS (Rodrigues-Sousa T. et 
Chapter 3 – Discussion and Conclusion 
 
61 
 
al. 2014). Having this in consideration, ROS absence increases the susceptibility for 
colitis chronicity. Furthermore, as a consequence of the elevated NO production, the 
immune response seems to be over-stimulated leading to chronic colonic inflammation. 
IBD is a recurrent disease affecting the modern world because of what we eat 
and how we live. Having in account that this disease may evolve into adenocarcinoma, 
it is important to understand how it starts and when is the right time to introduce 
particular therapies. In that line of thought the next step is to try to understand the stages 
of this progression into carcinogenesis, and modulate its evolution with different 
therapeutic approaches. For example, it will be interesting to use immune system 
modulation in order to control the disease evolution, maintaining a tight regulation of 
ROS production to control its potential harmful actions. Our model seems to be a good 
model for carcinogenesis since usually more cycles of DSS are needed in order to get 
dysplasia and we got it after two cycles of induction (Cooper, Murthy et al. 2000). 
Eventually, exploring models with other NOX2-subunits mutations will yield further 
insights into the role of this complex in colon function and protection. 
This study presents another perspective of ROS role in inflammation and 
dysplasia: ROS concentration should be kept in a very thigh balance, otherwise its 
benneficts/damages might cause immune-disregulation. Typically, the deterimental role 
of ROS in cancer and other diseases is focused on its high levels. However, we 
challenged this paradigm as we have shown that its absence compromises the ability of 
the immune system to regulate and react its response against previous challenges. 
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